No Data
No Data
Piper Sandler Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $115
Ultragenyx Pharma Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $115
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Are Not Doing Enough For Some Investors
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet Therapeutics SAS, Ultragenyx Pharmaceutical and Nobelpharma
Morgan Stanley Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $64